Overview

• The FDA granted accelerated approval for Wegovy to treat adults with moderate-to-advanced noncirrhotic MASH based on a Phase III trial.
• ESSENCE part 1 demonstrated that 63% of patients on Wegovy achieved steatohepatitis resolution at week 72 versus 34% with placebo.
• Novo Nordisk introduced a $499 per month self-pay option for Ozempic and Wegovy through its NovoCare service and partners like GoodRx.
• The combined regulatory nod and pricing plan drove a roughly 4% uptick in Novo Nordisk’s share price on Monday.
• Novo is suing more than 130 pharmacies and telehealth firms over unapproved compounded semaglutide and faces rivalry from Eli Lilly’s tirzepatide label expansions.